Synaptics Incorporated (SYNA)

Marinus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 29, 2025	Jun 29, 2024	Jun 24, 2023	Jun 25, 2022	Jun 26, 2021	Jun 27, 2020
Revenue	1,039	959.4	1,355	1,740	1,340	1,334
Revenue Growth (YoY)	10.60%	-29.20%	-22.11%	29.87%	0.43%	-9.39%
Cost of Revenue	566.6	519.6	639.2	796.6	728.4	790.8
Gross Profit	472.3	439.8	715.9	943.1	611.2	543.1
Selling, General & Admin	173	161.3	175	168.4	144.9	127
Research & Development	337.6	336.3	351.2	367.3	313.4	302.5
Operating Expenses	526.6	514.9	561.6	574.4	491	441.2
Operating Income	-54.3	-75.1	154.3	368.7	120.2	101.9
Interest Expense	-50.8	-65.3	-55.5	-30.2	-29.5	-22.5
Interest & Investment Income	33.9	42.3	27.2	3	2.9	7.9
Earnings From Equity Investments	-	-	-	1.6	-9.1	-2
EBT Excluding Unusual Items	-71.2	-98.1	126	343.1	84.5	85.3
Merger & Restructuring Charges	-16.9	-10.5	-	-18.3	-7.4	-33
Gain (Loss) on Sale of Assets	-	-	-	5.4	34.2	105.1
Asset Writedown	-29.8	-16	-	-	-	-
Other Unusual Items	-6.5	-	-	-8.1	-0.3	-
Pretax Income	-124.4	-124.6	126	322.1	111	157.4
Income Tax Expense	-289.6	-250.2	52.4	64.6	31.4	38.6
Net Income	165.2	125.6	73.6	257.5	79.6	118.8
Net Income to Common	165.2	125.6	73.6	257.5	79.6	118.8
Net Income Growth	-	70.65%	-71.42%	223.49%	-33.00%	-
Shares Outstanding (Basic)	40	39	40	39	35	34
Shares Outstanding (Diluted)	40	40	40	41	38	35
Shares Change (YoY)	2.17%	-1.24%	-1.23%	6.27%	10.06%	0.58%
EPS (Basic)	4.18	3.20	1.86	6.60	2.29	3.54
EPS (Diluted)	4.13	3.16	1.83	6.33	2.08	3.41
EPS Growth	-	72.68%	-71.09%	204.33%	-39.00%	-
Free Cash Flow	122.9	102.1	297.3	431.6	298.1	205.5
Free Cash Flow Per Share	3.07	2.57	7.40	10.60	7.78	5.91
Gross Margin	45.46%	45.84%	52.83%	54.21%	45.63%	40.72%
Operating Margin	-5.23%	-7.83%	11.39%	21.19%	8.97%	7.64%
Profit Margin	15.90%	13.09%	5.43%	14.80%	5.94%	8.91%
Free Cash Flow Margin	11.83%	10.64%	21.94%	24.81%	22.25%	15.41%
EBITDA	76.2	34.1	312.1	516.2	251.9	180
EBITDA Margin	7.33%	3.55%	23.03%	29.67%	18.80%	13.49%
D&A For EBITDA	130.5	109.2	157.8	147.5	131.7	78.1
EBIT	-54.3	-75.1	154.3	368.7	120.2	101.9
EBIT Margin	-5.23%	-7.83%	11.39%	21.19%	8.97%	7.64%
Effective Tax Rate	-	-	41.59%	20.06%	28.29%	24.52%

Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q